Physician profile
Niketa C Shah
NPI 1134350499
$28,803.81
in general payments reported to CMS, 2019-2025
10 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2021: $2,407 · 2023: $4,231 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,125 · Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,125.00 |
| Food and Beverage | $257.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22,048.01 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $4,125.00 | 2023 | Imbruvica |
| Kadmon Pharmaceuticals LLC | $2,407.00 | 2021 | |
| Syndax Pharmaceuticals, INC. | $135.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $72.68 | 2019 | |
| Kedrion Biopharma, INC. | $15.97 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niketa Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.